Journal article
Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration‐resistant prostate cancer treated with custirsen
Abstract
Elevated levels of clusterin (CLU), a stress-induced and secreted cytoprotective chaperone, are associated with advanced tumor stage, metastasis, treatment resistance, and adverse outcome in several cancers. Custirsen, a second-generation antisense oligonucleotide, inhibits CLU production in tumor cells and reduces serum CLU levels. A Phase 2 study evaluated custirsen in combination with second-line chemotherapy in men with metastatic …
Authors
Blumenstein B; Saad F; Hotte S; N K; Eigl B; Gleave M; Jacobs C
Journal
Cancer Medicine, Vol. 2, No. 4, pp. 468–477
Publisher
Wiley
Publication Date
August 2013
DOI
10.1002/cam4.93
ISSN
2045-7634